News

The approval of the company’s New Drug Application (NDA) was granted under the US President's Emergency Plan for AIDS Relief (PEPFAR). Following the approval, Mylan said that it

SECURE study is a prospective, multi-center, randomized and double-blind placebo-controlled trial designed to assess patients with moderate to severe ulcerative colitis. SB012 is an enema formulation of hgd40,

The Phase II trial (BGBC007) follows a two-stage design: it is an open label, multi-centre study of bemcentinib in combination with KEYTRUDA in patients with previously treated, locally

As a result of the Acquisition, DanDrit owns a perpetual, fully paid up, royalty free, sublicensable, exclusive, license to new technology platforms for the treatment of HIV, including

The improvement was seen 12 weeks after treatment with Taltz injection, in comparison to placebo, said Lilly. The company said that 92% of patients treated with Taltz had

Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor, which showed speedy and sustained long term efficacy in treating patients with moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondilytis

As announced in a press release dated November 7, 2017, a previous U.S Phase III study did not meet its primary endpoint – change in worst leg pain

QVAR® RediHaler™ is the first and only breath-actuated aerosol inhaled corticosteroid for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and

The approval is for the expanded use of Imfinzi to treat NSCLC patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). Imfinzi, which